"description","label","text","uuid:ID","instanceType","name","id"
"Main objective","","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","ebc24ef2-fa82-4edb-ab4b-4a0b5b6b7701","Objective","OBJ1","Objective_1"
"Safety","","To document the safety profile of the xanomeline TTS.","9b5d900a-207e-409d-a866-5b8624994ac6","Objective","OBJ2","Objective_2"
"Behaviour","","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","293fddb9-8235-402d-bc4f-99de5804b668","Objective","OBJ3","Objective_3"
"","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","d0a2d069-44d5-4e18-b99d-291fb43abe79","Objective","OBJ4","Objective_4"
"","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","e5a99b7e-21f8-43ce-93c6-9321f7c9f7b0","Objective","OBJ5","Objective_5"
"","","To assess the treatment response as a function of Apo E genotype.","c5f13fa4-22e0-4c1d-9e0b-3de68a273810","Objective","OBJ6","Objective_6"
